Navigation Links
Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference
Date:11/2/2007

potent inhibitor of the ADAM-10 and MMP-2 metalloprotease enzymes, targets of significant interest because of their important role in renal fibrosis and impairment. XL784 was specifically optimized to be matrix metalloprotease-1 (MMP-1) sparing, thus potentially significantly enhancing its safety profile and enabling higher dosing compared with other previously studied metalloprotease inhibitors. Results of single and repeat dose phase 1 clinical trials of XL784 administered orally to 70 healthy volunteers demonstrated that XL784 has attractive safety and pharmacokinetic profiles.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GSK, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to the future development and potential safety and efficacy of XL784. Words such as "may," "expect," "suggest," "potentially" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current expectations. Forward-looking statements involve risks and uncertainties. Exelixis' actual results and the timing of events co
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015 Sleep ... sleep therapy, and HGE Health Care Solutions, a ... announced today a comprehensive sleep management and cost ... (OSA). OSA is a chronic medical ... sleep and may increase a patient,s risk for ...
(Date:9/1/2015)... 1, 2015   Millstone Medical Outsourcing announced today ... in Olive Branch, MS. Now totaling ... facility has added the capacity required to meet the ... "This expansion gives us the opportunity to grow in parallel ... Millstone MS. "Two and a half years ago we were ...
(Date:9/1/2015)... Belgium , Sept. 1, 2015 VolitionRx ... on developing blood-based diagnostic tests for a broad range of ... Executive Officer, Cameron Reynolds , is scheduled to attend ... is being held September 9-10, 2015 in Boston, ... on September 10. Wells Fargo Securities Research ...
Breaking Medicine Technology:Sleep Specialists, LLC and HGE Health Care Solutions Announce Comprehensive Sleep Program 2Millstone Medical Outsourcing Announces Olive Branch Expansion 2VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 2VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 3VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 4
... in Ohio supported by the biopharmaceutical research sector would ... new taxes in the Medicare prescription drug program – ... to technical work, manufacturing to construction and other building ... sector supports a broad array of high-quality jobs. ...
... Sept. 27, 2011 Visiting Nurse Services of ... home health agencies, announces that it has entered ... advanced home telehealth technology to patients with chronic ... Experts in Telehealth(SM), is a world class developer, ...
Cached Medicine Technology:Research Demonstrates Possible Ohio Job Losses from Sectors Supported by Biopharmaceutical Companies 2Research Demonstrates Possible Ohio Job Losses from Sectors Supported by Biopharmaceutical Companies 3Visiting Nurse Services of Connecticut Selects Cardiocom® As Its New Telehealth Vendor 2
(Date:9/1/2015)... San Diego, CA (PRWEB) , ... September 01, 2015 , ... ... with Bellus Academy will present “The Beauty Behind the Fashion” on Thursday, Oct. ... San Diego® (FWSD), will shine the spotlight on the collaboration between fashion and professional ...
(Date:9/1/2015)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) has once again ... 50 Report that recognizes companies that provide the best career opportunities for Hispanic women ... number 24 to 21 of the 50 Best Companies for Latinas. The LATINA Style ...
(Date:9/1/2015)... ... 01, 2015 , ... Consumers overwhelmingly prefer to have their ... according to a new survey that also offers insight on why that is ... which reflects views on cosmetic medical treatments and ratings for 10 specific procedures ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... creates negative pressure inside a wound to remove exudates, fluid, and infectious materials ... (comprising portable devices, stand-alone devices, disposable devices, and canisters, etc.) is projected to ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... ranked a top-five hospital by U.S. News & World Report, to provide breaking ... , Editorial and marketing groups within OncLive, which provides oncologists resources and ...
Breaking Medicine News(10 mins):Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3
... New Delhi: The National AIDS Control Organization (NACO) has ... to provide free anti-retroviral treatment (ART). //The count of ... on the anvil. , ,These centers will support ... the services of exclusive doctors, counselors and laboratory technicians ...
... or get the consent of one or both parents before ... to a Florida State University law professor in Tallahassee, Fla. ... and Thomas Stratmann, professor of economics at George Mason University, ... of gonorrhea among teenage girls as a measure of risky ...
... reduce their risk of becoming obese children, even if ... a study led by a researcher at the University ... ,The findings contradict an earlier, smaller study that found ... diabetes had poor glucose tolerance, a precursor to diabetes, ...
... self-image as the “strong, silent type” and the stigma ... less likely than women to be referred to studies ... recognize and express symptoms of depression, according to clinicians ... UC Davis Department of Psychiatry and Behavioral Sciences. ...
... tennis elbow and a wait and watch approach may be ... Australian researchers tested this approach in one group of volunteers, ... ,A second group were given a local ... The final group received eight treatments of physiotherapy of 30 ...
... amphetamine abuse in the Asia-Pacific region has hit high levels ... problem threatening Asia that is this big is a problem ... Australia as is the security of Australia in terms of ... the United Nations Office of Drugs and Crime told AFP. ...
Cached Medicine News:Health News:Abortion Notification, Consent Laws Reduce Risky Teen Sex 2Health News:Breast-Feeding May Reduce Childhood Obesity 2Health News:Stereotypes Contribute to Older Men Seeking, Receiving Depression Care Less Frequently 2Health News:Stereotypes Contribute to Older Men Seeking, Receiving Depression Care Less Frequently 3Health News:Stereotypes Contribute to Older Men Seeking, Receiving Depression Care Less Frequently 4Health News:Steroids Ineffective In Tennis Elbow 2
... The CSV-1000CVA20/30 test face provides three contrast ... acuity from 20/16 to 20/100. This test is ... such as associated with contact lens evaluation or ... of the test provide the same contrast and ...
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
Contrast sensitivity testing, glare sensitivity testing and ETDRS acuity testing are provided in the self standardized CSV-1000 instrument. Patented photocell circuitry automatically monitors and cal...
... Sample of Topics Covered: diagrams, ... tx's and differentials of a ... eyes, vision loss, pupillary abnormalities, ... infections, medications, cataracts, vision correction ...
Medicine Products: